Paul Hastings Earns Runner-Up Recognition for AbbVie/Allergan $56 Million Verdict

Paul Hastings Secures Major Win for Allergan, Earning Runner-Up for “Litigator of the Week.” The firm successfully defended all three of Allergan’s asserted patents in a significant case against Revance Therapeutics.

This victory involved a product that directly competes with Allergan’s well-known Botox. A jury awarded Allergan $56 million in upfront payments, reflecting a 27% reasonable royalty rate.

Leading the charge was eric Dittmann, global co-chair of Paul Hastings’ Intellectual Property practice. He was supported by partners Melanie Rupert and Isaac ashkenazi, along with associates Krystina Ho, Carl Minniti, Karthik Kasasaneni, Vladimir Semendyai, David Valente, and Amanda Taylor.

This recognition highlights the exceptional skill and dedication of litigators who navigate complex intellectual property landscapes.Such outcomes underscore the critical role of robust patent protection in fostering innovation and fair competition within the pharmaceutical and aesthetic industries.

The Paul Hastings team’s success in this high-stakes litigation serves as a powerful reminder of the importance of strategic legal counsel in safeguarding valuable intellectual assets. it also emphasizes the financial and market implications of patent disputes in competitive product sectors.

What strategic elements contributed to Paul Hastings’ favorable outcome in the abbvie/Allergan Restasis case?

Key Takeaways from the Landmark Case

Paul Hastings LLP has received meaningful recognition as runner-up in The national Law journal’s 2025 Litigation Department of the Year competition, specifically lauded for its prosperous portrayal of AbbVie in a high-stakes dispute with Allergan concerning the blockbuster drug Restasis. The firm secured a $56 million verdict, a significant win in the complex world of pharmaceutical patent litigation. This achievement highlights Paul Hastings’ prowess in intellectual property law, particularly within the biopharmaceutical sector.

The AbbVie/Allergan Restasis Patent Dispute: A Deep Dive

The core of the case revolved around patents protecting Restasis, a medication used to treat chronic dry eye. Allergan, before its acquisition by AbbVie, had strategically attempted to shield its market exclusivity through a series of patent filings, frequently enough referred to as “patent thickets.” AbbVie challenged the validity of several of these patents, arguing they were improperly obtained and did not represent genuine innovation.

Here’s a breakdown of the key elements:

Patent Validity Challenges: AbbVie’s legal team meticulously dissected Allergan’s patent claims, presenting evidence of prior art and arguing against the non-obviousness of the patented inventions.

Hatch-Waxman Litigation: The case fell under the Hatch-Waxman Act, which governs the approval of generic drugs. This meant the litigation involved complex considerations regarding patent challenges and potential market entry by generic competitors.

District Court Ruling: The District Court of Delaware ultimately sided with AbbVie, invalidating key patents held by Allergan. This paved the way for potential generic competition and substantially impacted the market for Restasis.

The $56 Million Verdict: The verdict represented damages related to Allergan’s alleged infringement of AbbVie’s intellectual property rights.

Paul Hastings’ Strategic Approach to Litigation

Paul Hastings’ success wasn’t simply about legal arguments; it was about a complete and strategic approach to litigation.Several factors contributed to their favorable outcome:

Expert Witness Testimony: The firm effectively utilized expert witnesses in the fields of chemistry, pharmacology, and patent law to bolster their arguments regarding patent invalidity.

Document Discovery & Analysis: A thorough review and analysis of millions of documents were crucial in uncovering evidence supporting AbbVie’s claims. This included internal Allergan communications and prior art references.

Focused Legal Team: Paul Hastings assembled a dedicated team of experienced litigators specializing in pharmaceutical patent disputes. This specialized knowledge proved invaluable.

Strong Cross-Examination: The firm’s attorneys skillfully cross-examined Allergan’s witnesses, challenging their credibility and undermining their arguments.

Implications for the pharmaceutical Industry

The AbbVie/allergan Restasis case has broader implications for the pharmaceutical industry, particularly concerning patent litigation strategies.

Patent thickets Under Scrutiny: The case serves as a cautionary tale for pharmaceutical companies attempting to build impenetrable “patent thickets” around their products. Courts are increasingly scrutinizing such strategies.

Importance of Genuine Innovation: The ruling underscores the importance of demonstrating genuine innovation when seeking patent protection. Incremental changes to existing drugs may not be sufficient to warrant a patent.

Hatch-Waxman litigation Trends: The case highlights the ongoing challenges and complexities of Hatch-Waxman litigation,where generic drug manufacturers frequently challenge the validity of branded drug patents.

Increased Litigation Costs: Pharmaceutical patent litigation is notoriously expensive. This case reinforces the need for companies to carefully assess the risks and benefits before initiating or defending patent lawsuits.

Paul Hastings’ Continued Success in IP Litigation

This runner-up recognition builds on Paul Hastings’ established reputation as a leading firm in intellectual property litigation. They consistently represent major pharmaceutical companies in high-stakes disputes, demonstrating a deep understanding of the industry’s unique challenges and legal landscape. Their expertise extends beyond patent litigation to include trademark, copyright, and trade secret disputes. The firm’s commitment to innovation and client service continues to drive its success in this competitive field.